loader image
Friday, December 19, 2025
65.2 F
McAllen
- Advertisement -

New COVID-19 Vaccine Data;  Protection Gained by 3rd and 4th Doses

Translate to Spanish or other 102 languages!

A third and fourth COVID-19 vaccine dose offered substantial protection among adults with healthy immune systems who were eligible to receive them during Omicron variant evolution in early 2022, according to a new MMWR published today. The findings of this study, in conjunction with recently published data showing people infected with BA.2 may also have antibodies that can protect against illness with BA.5, suggest that currently available vaccines may provide protection against serious illness caused by the currently circulating BA.5 variant. Image for illustration purposes
A third and fourth COVID-19 vaccine dose offered substantial protection among adults with healthy immune systems who were eligible to receive them during Omicron variant evolution in early 2022, according to a new MMWR published today. The findings of this study, in conjunction with recently published data showing people infected with BA.2 may also have antibodies that can protect against illness with BA.5, suggest that currently available vaccines may provide protection against serious illness caused by the currently circulating BA.5 variant. Image for illustration purposes

Mega Doctor News

- Advertisement -

A third and fourth COVID-19 vaccine dose offered substantial protection among adults with healthy immune systems who were eligible to receive them during Omicron variant evolution in early 2022, according to a new MMWR published today. The findings of this study, in conjunction with recently published data showing people infected with BA.2 may also have antibodies that can protect against illness with BA.5, suggest that currently available vaccines may provide protection against serious illness caused by the currently circulating BA.5 variant.

To evaluate effectiveness of 2, 3, and 4 doses of mRNA COVID-19 vaccines (Pfizer-BioNTech or Moderna) among adults with healthy immune systems, experts examined VISION Network data on more than 214,000 emergency department/urgent care visits and more than 58,000 hospitalizations with a COVID-19–like illness diagnosis in 10 U.S. states from mid-December 2021 through mid-June 2022. Study findings show:

  • When BA.1 was the predominant variant, vaccine effectiveness (VE) was 61% for two doses against COVID-19-associated hospitalizations; VE increased to between 85%–92% after receipt of a third/booster dose.
  • When BA.2/BA.2.12.1 became predominant, vaccine effectiveness with two doses was 24% against COVID-19-associated hospitalizations and increased to 52%–69% after a third/booster dose.
  • Patterns were similar for emergency department and urgent care encounters, with lower VE during BA.2/BA.2.12.1 predominance and higher VE with 3 or 4 doses compared to VE with 2 doses.
  • Among adults ages 50 years and older during BA.2/BA.2.12.1, vaccine effectiveness against COVID-19–associated hospitalization was 55% more than 4 months after a booster/third dose and increased to 80% more than a week after the fourth dose

COVID-19 vaccines remain our single most important tool to protect people against serious illness, hospitalization, and death. Getting vaccinated now will not prevent you from getting an authorized variant-specific vaccine in the fall or winter when they are recommended for you.  Given recent increases in deaths and hospitalizations associated with the BA.5 variant, everyone should stay up to date with recommended COVID-19 vaccinations, including additional booster doses for those who are moderately to severely immunocompromised and adults over 50.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Heart Association Highlights 2025’s Major Research Findings

In 2025, cardiovascular investigators worldwide reported findings that could help fill important gaps in preventing and managing conditions including high blood pressure, stroke, heart failure, dangerous blood clots and aortic stenosis.

DHR Health and Brownsville Join Forces on Major Hospital Expansion

The City of Brownsville and DHR Health announced a new public-private partnership to expand DHR Health Brownsville, marking a major investment in local healthcare and economic development

Uniting Experts to Revolutionize Cancer Treatment

More than 70% of all cancers are impacted by mutations caused by a group of DNA-editing enzymes that drives tumor growth and drug resistance. The apolipoprotein B mRNA-editing enzyme catalytic polypeptide, or APOBEC, family, is a dominant factor in many cancers including bladder, breast, cervical, head and neck and lung.

Early Findings Show Breast Cancer Vaccine Produces Immune Response

Cleveland Clinic released its findings from the first phase of the clinical trial for the preventive breast cancer vaccine. 
- Advertisement -
×